Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease.

Palvella Therapeutics

Derived from the Finnish word for “to serve”, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.

Ligand Pharmaceuticals

Adams Street Partners

Agent Capital

Samsara BioCapital

Nolan Capital

Opaleye Management

BioAdvance

BVF Partners

CAM Capital

Gore Range Capital

Petrichor Healthcare Capital Management

Palvella is proud to serve individuals with serious, rare genetic skin diseases and raise awareness for the 300 million people worldwide living with a rare disease.

@Pachyonychia Congenita (PC) Project @Gorlin Syndrome Alliance 
#rarediseaseday #showyourstripes

COM:PALVELLATX

Palvella Therapeutics

Financials Not Available